

UNITED THERAPEUTICS CORP

Form 8-K

September 23, 2003

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15 (d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 22, 2003

United Therapeutics Corporation

(Exact Name of Registrant as Specified in Charter)

Delaware

(State or Other
Jurisdiction of
Incorporation)

000-26301

(Commission
File Number)

52-1984749

(I.R.S. Employer
Identification Number)

1110 Spring Street
Silver Spring, MD

(Address of Principal Executive Offices)

20910

(Zip Code)

Registrant's telephone number, including area code:

(301) 608-9292

Item 5. Other Events.

On September 22, 2003, United Therapeutics Corporation (the Company) issued a press release announcing that the French Regulatory Agency has recommended that Remodulin not be approved in France based on insufficient demonstration of clinical efficacy for the claimed indication. A copy of the press release is attached hereto and incorporated herein by this reference.

Item 7. Exhibits

(c) Exhibits

<u>Exhibit No.</u>	<u>Description of Exhibit</u>
99.1	Press release dated September 22, 2003

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

UNITED THERAPEUTICS CORPORATION

Dated: September 23, 2003

By: /s/ Paul A. Mahon
Name: Paul A. Mahon
Title: General Counsel

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description of Exhibit</u>
99.1	Press Release dated September 22, 2003